The Innovation Firm

IP News Alerts

The European Patent Office Extends the Time for Filing Divisional Applications
October 21, 2013 - Hamilton Brook Smith Reynolds Alert
By: Mary K. Murray, Ph.D.
Updated January 2014 to Reflect New Fee Rates The two-year limitation on filing a divisional application in Europe is being repealed. After April 14, 2014, an Applicant can file...
More »

Eligibility of Computer and Software-Related Patents is Again Before the Supreme Court
September 23, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce and Mary K. Murray, Ph.D.
Following its decision that isolated human genes are not patentable, the U.S. Supreme Court is now being asked to provide a clear demarcation between what is and is not patent eligible...
More »

Filing a Petition for Inter Partes Review or Post-Grant Review Can Stay Other Patent Office Post-Grant Proceedings
August 23, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce
Filing of a petition for inter partes review, or post-grant review, under the America Invents Act (AIA) can prompt a stay of ex parte reexamination.   The Order On August...
More »

USPTO Reexamination Trumps Federal Court Opinions of Patent Validity
August 21, 2013 - Hamilton Brook Smith Reynolds Alert
By: David E. Brook
A party accused of infringing a patent can fail to invalidate the patent in the courts but still win based on a decision of invalidity in a reexamination proceeding at the United...
More »

Supreme Court Rules on Patentability of Genes in Myriad
June 19, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce
Isolated genes are not eligible for patent protection. cDNA is patent eligible under § 101. Patent eligibility requires an "act of invention." United States Patent...
More »

Third-Party Clinical Trials Not Considered “Public Use”
June 18, 2013 - Hamilton Brook Smith Reynolds Alert
By: Kristen K. Salvaggio
Public use inquiry is focused on the knowledge obtained by the public during clinical trial of a drug, rather than on the extent of use of the drug. Confidentiality controls implemented...
More »

Bowman v. Monsanto Co. Raises Concerns for Buyers of Patented Self-Replicating Products
June 13, 2013 - Hamilton Brook Smith Reynolds Alert
Contributing Writer Chace Craig from Hamilton Brook Smith Reynolds The doctrine of patent exhaustion does not protect replication of genetically modified soybean seeds for...
More »

Isolated Human Genes Are Not Patentable; cDNA Is Patent Eligible Subject Matter
June 13, 2013 - Hamilton Brook Smith Reynolds Alert
The Supreme Court unanimously ruled today in Association for Molecular Pathology v. Myriad Genetics that genes (naturally occurring DNA segments) isolated from the human body are not...
More »

« previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | next »

The European Patent Office Extends the Time for Filing Divisional Applications
October 21, 2013 - Hamilton Brook Smith Reynolds Alert
By: Mary K. Murray, Ph.D.
Updated January 2014 to Reflect New Fee Rates The two-year limitation on filing a divisional application in Europe is being repealed. After April 14, 2014, an Applicant can file...
More »

Eligibility of Computer and Software-Related Patents is Again Before the Supreme Court
September 23, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce and Mary K. Murray, Ph.D.
Following its decision that isolated human genes are not patentable, the U.S. Supreme Court is now being asked to provide a clear demarcation between what is and is not patent eligible...
More »

Filing a Petition for Inter Partes Review or Post-Grant Review Can Stay Other Patent Office Post-Grant Proceedings
August 23, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce
Filing of a petition for inter partes review, or post-grant review, under the America Invents Act (AIA) can prompt a stay of ex parte reexamination.   The Order On August...
More »

USPTO Reexamination Trumps Federal Court Opinions of Patent Validity
August 21, 2013 - Hamilton Brook Smith Reynolds Alert
By: David E. Brook
A party accused of infringing a patent can fail to invalidate the patent in the courts but still win based on a decision of invalidity in a reexamination proceeding at the United...
More »

Supreme Court Rules on Patentability of Genes in Myriad
June 19, 2013 - Hamilton Brook Smith Reynolds Alert
By: N. Scott Pierce
Isolated genes are not eligible for patent protection. cDNA is patent eligible under § 101. Patent eligibility requires an "act of invention." United States Patent...
More »

Third-Party Clinical Trials Not Considered “Public Use”
June 18, 2013 - Hamilton Brook Smith Reynolds Alert
By: Kristen K. Salvaggio
Public use inquiry is focused on the knowledge obtained by the public during clinical trial of a drug, rather than on the extent of use of the drug. Confidentiality controls implemented...
More »

Bowman v. Monsanto Co. Raises Concerns for Buyers of Patented Self-Replicating Products
June 13, 2013 - Hamilton Brook Smith Reynolds Alert
Contributing Writer Chace Craig from Hamilton Brook Smith Reynolds The doctrine of patent exhaustion does not protect replication of genetically modified soybean seeds for...
More »

Isolated Human Genes Are Not Patentable; cDNA Is Patent Eligible Subject Matter
June 13, 2013 - Hamilton Brook Smith Reynolds Alert
The Supreme Court unanimously ruled today in Association for Molecular Pathology v. Myriad Genetics that genes (naturally occurring DNA segments) isolated from the human body are not...
More »

« previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | next »

Back to the Top